4534
Mochida Pharmaceutical Co., Ltd.
2026/03/30
Mochida Pharmaceutical will acquire the manufacturing and marketing approval of gout and hyperuricemia treatment "Uris Tablets" and related assets from Fuji Pharma Co., Ltd. for 13.5 billion yen, scheduled for execution on June 30, 2026.
